Table 1.

Worsening HF included in clinical trial study designs: VICTORIA trial versus VICTOR trial.

	VICTORIA [9] (Patients: 5050)	VICTOR [48] (Patients: 6000)
	Vericiguat 2526 female 1921 male Placebo 2524 female 1921 male	Ongoing
Study drug	Vericiguat vs. placebo	Vericiguat vs. placebo
Key inclusion criteria	Chronic HF with NYHA functional class II–IV EF < 45% Receiving HF GDMT Prior HF hospitalization within 6 months or outpatient intravenous diuretic for HF within 3 months Elevated NT-proBNP levels	Chronic HF with NYHA functional class II–IV EF ≤ 40% Elevated NT-proBNP levels
Primary endpoint	Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization	Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization The first event of CV death or HF hospitalization as confirmed by a clinical event committee (CEC)
Select secondary endpoints	Time to CV death Time to first HFH Time to total (first and recurrent) HFHs Time to total first occurrence of composite of all-cause mortality or HFH Time to all-cause mortality Safety and tolerability	Time to first occurrence of CV First event of CV death as confirmed by CEC Time to first occurrence of HF hospitalization The first event of HF hospitalization as confirmed by CEC Time to total HF hospitalizations, all events of HF hospitalization as confirmed by CEC Safety and tolerability
Randomized Double-blind 1:1	2.5 mg od/5 mg od/10 mg od (up-titration at 2-week intervals) Placebo	2.5, 5.0, or 10.0 mg orally once daily Placebo
Median follow-up	10.8 months	40.0 months